Marker Therapeutics, Inc. (MRKR) › Cash & EquivalentsMarker Therapeutics, Inc. (MRKR) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2017-12-31: $5.13M2018-12-31: $61.75M2019-12-31: $43.90M2020-12-31: $21.35M2021-12-31: $42.35M2022-12-31: $11.78M2023-12-31: $15.11M2024-12-31: $19.19M2025-12-31: $16.07M$16.07M2017-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$16.07M-16.3%2026-03-18Balance as of period end2024-12-31$19.19M+27.0%2026-03-18Balance as of period end2023-12-31$15.11M+28.3%2025-03-31Balance as of period end2022-12-31$11.78M-72.2%2024-03-26Balance as of period end2021-12-31$42.35M+98.3%2023-03-22Balance as of period end2020-12-31$21.35M-51.4%2022-03-17Balance as of period end2019-12-31$43.90M-28.9%2021-03-09Balance as of period end2018-12-31$61.75M+1103.8%2020-03-12Balance as of period end2017-12-31$5.13M—2019-03-15Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)